



Universiteit  
Leiden  
The Netherlands

## Nociception monitoring

Meijer, F.S.

### Citation

Meijer, F. S. (2022, November 17). *Nociception monitoring*.  
Retrieved from <https://hdl.handle.net/1887/3486441>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of  
doctoral thesis in the Institutional  
Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3486441>

**Note:** To cite this publication please use the final published  
version (if applicable).



# 3

## **DOES NOCICEPTION MONITOR- GUIDED ANESTHESIA AFFECT OPIOID CONSUMPTION? A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS**

Fleur S. Meijer MD,<sup>1</sup> Marieke Niesters MD PhD,<sup>2</sup> Monique van Velzen PhD,<sup>3</sup>  
Chris H. Martini MD PhD,<sup>4</sup> Erik Olofsen PhD,<sup>5</sup> Ruth Edry MD PhD,<sup>6</sup>  
Daniel I. Sessler MD PhD,<sup>7</sup> Eveline L.A. van Dorp MD PhD,<sup>8</sup>  
Albert Dahan MD PhD,<sup>9</sup> Martijn Boon MD PhD<sup>10</sup>

1. Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands; f.s.meijer@lumc.nl

2. Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands; m.niesters@lumc.nl

3. Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands; m.van\_velzen@lumc.nl

4. Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands; c.h.martini@lumc.nl

5. Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands; e.olofsen@lumc.nl

6. Department of Anesthesiology, Rambam Medical Centre, The Ruth and Bruce Rappaport Faculty of Medicine,

Technion Institute of Technology, Haifa, Israel; ruedry@gmail.com

7. Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, Ohio. ds@or.org

8. Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands; e.l.a.van\_dorp@lumc.nl

9. Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands; a.dahan@lumc.nl

10. Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands; m.boon@lumc.nl

## ABSTRACT

### Purpose

Monitors that estimate nociception during anesthesia may be used to guide opioid administration to optimize anesthesia care and possibly outcome. We reviewed the literature to evaluate current evidence of the effect of nociception-guided management over standard anesthesia practice during surgery.

### Methods

A systematic review of the literature on the effect of nociception monitoring on anesthesia practice was conducted. Reports were eligible if they compared nociception-guided anesthesia to standard practice during surgery. Primary endpoint of this review is intraoperative opioid consumption. Secondary endpoints included hemodynamic control, postoperative pain and pain treatment.

### Results

We identified 12 randomized controlled trials that compared one of five different nociception monitoring techniques to standard anesthesia care. Most studies were single center studies of small sample size. Six studies reported intraoperative opioid consumption as primary outcome. There was considerable variability with respect to surgical procedure and anesthesia technique. For nociception monitors that were investigated by more than one study, analysis of the pooled data was performed. The Surgical Plethysmographic Index was the only monitor for which an opioid sparing effect was found. For the other monitors, either no effect was detected, or pooled analysis could not be performed due to paucity of study data. On secondary outcomes, no consistent effect of nociception-guided anesthesia could be established.

### Conclusions

Although some nociception monitors show promising results, no definitive conclusions regarding the effect of nociception monitoring on intraoperative opioid consumption or other anesthesia related outcome can be drawn.

### Key words

Nociception monitoring, opioid consumption, systematic review

## INTRODUCTION

General anesthesia is intended to produce a state of unconsciousness combined with suppression of nociception, allowing the patient to undergo invasive surgical procedures without undue harm or awareness. Nociception is defined by the International Association for the study of Pain as *the neural process of encoding noxious stimuli*, causing autonomic and/or behavioral responses such as elevation of blood pressure or motor withdrawal reflexes; noxious stimuli are actually or potentially tissue damaging events that occur during surgery. <sup>[1]</sup> Nociception is generally suppressed by administration of potent opioid analgesics.

Clinicians usually estimate nociception by evaluating hemodynamic responses, along with lacrimation, sweating, increase in pupil diameter or movement. Recently, nociception monitors have been introduced to track nociception during anesthesia and guide administration of analgesics, usually opioids. Since inadequate opioid administration is associated with unwanted hemodynamic responses (*e.g.* hypertension and hypotension), reliable nociception monitors may help optimize anesthetic management. Evidence from preclinical validation studies show that these monitors distinguish noxious and non-noxious events far better than hemodynamic responses.<sup>[2-6]</sup>

Various nociception monitors are already available, and others are being developed. All use algorithms to assess various physiological variables and produce numerical indexes (see table 1). In addition, the value of nociception monitors is increasingly assessed in clinical settings, where they are compared to standard anesthesia care. We intended to evaluate current evidence of the effect of nociception-guided management on intraoperative opioid consumption and other anesthesia related outcomes. To this end, a systematic search was conducted to identify reports that assessed intraoperative nociception monitoring *versus* routine anesthetic management on intraoperative opioid consumption. If possible, analysis of pooled data was performed to synthesize current evidence.

## MATERIALS AND METHODS

Our goal was to determine whether the use of a monitor or algorithm that estimates patients' nociceptive state during general anesthesia alters anesthesia management with respect to the administration of opioids. Secondary aims were to evaluate the effect of nociception monitoring on hemodynamic parameters, time related variables (*eg.* time to extubation) and postoperative pain score and opioid consumption. We searched for trials in which the primary endpoint was the amount of opioid analgesic medication given during anesthesia. All available nociception monitors were considered, along with indices derived from the electroencephalogram or evoked potentials. The systematic review was conducted in accordance with the PRISMA statements. A planned meta-analysis was registered at PROSPERO ([www.crd.york.ac.uk/prospero](http://www.crd.york.ac.uk/prospero)) under identifier 102913. Since there was so much heterogeneity among the included studies, a valid meta-analysis could not be conducted. Instead, pooled data were analyzed exclusively within unique monitors when available.

### Identification of relevant studies

On June 30, 2018 we searched the PubMed electronic database for inception for studies on nociception monitoring. The search strategy is given in Supplemental Document 1; no language or date restrictions were applied. To reduce the risk of missing relevant studies, we checked relevant review papers and a previous meta-analysis.<sup>[7]</sup> The title and abstracts of the retrieved studies were next step-wise evaluated for the following three criteria: (1) study in surgical patients, aged 18 years and older; (2) study performed during general anesthesia; and, (3) randomized trial of nociception monitor-guided administration of opioids *versus* standard clinical care in which analgesics were administered solely based on blood pressure and heart rate values. All papers meeting all criteria were read in full. Three reviewers (FM, AD, and RE) independently performed the selection procedure.

### Data extraction

The identified reports were searched for the following variables and these were extracted for the review if available: authors, country of origin, year of publication, number of subjects in each treatment group, type of opioid and anesthetic used, opioid consumption during surgery, anesthetic consumption

during surgery, duration of anesthesia, hypotension and/or bradycardia events, hypertension and/or tachycardia events, time from end-of-anesthesia or administration of reversal agent until extubation or emergence, duration of stay in the post-anesthesia care unit (PACU), average pain level in the PACU, and opioid consumption in the PACU.

Opioid consumption during surgery of opioids was transformed to morphine dose (in  $\text{mg.kg}^{-1}.\text{hr}^{-1}$ ) using the following conversion ratios: 1 mg morphine (intravenous) = 0.5 mg oxycodone = 10  $\mu\text{g}$  fentanyl = 1  $\mu\text{g}$  sufentanil = 10  $\mu\text{g}$  remifentanyl = 50  $\mu\text{g}$  alfentanil. These conversion rates are arbitrarily based on existing opioid potency data.<sup>[8]</sup>

### **Bias assessment**

Study quality was evaluated with the Cochrane Collaboration's tool for assessing risk of bias in randomized trials.<sup>[9]</sup> This tool considers six domains of bias: (1) selection bias which includes the presence of random sequence generation and allocation concealment; (2) performance bias which includes the blinding of participants and personnel; (3) detection bias which includes the blinding of outcome assessment; (4) attrition bias, which includes incomplete outcome data; (5) reporting bias which includes selective reporting; and (6) other bias. For each study, the presence of bias in each domain was assessed independently by two reviewers (FM and MN). Discrepancies in judgment were resolved by consensus and, when required a third reviewer was consulted (AD).

### **Data analysis**


Analyses of combined data per unique monitor were conducted using the statistical package R (version 3.5.0) with the metafor package.<sup>[10,11]</sup> Data were analyzed using random effects models, assuming two sources of variance, within-study error and between-study error. Heterogeneity was by measuring the degree of inconsistency in the studies' results ( $I^2$ ).

## **RESULTS**

### **Study selection**

The flow chart of the PubMed search is shown in Figure 1, which illustrates

retrieval of 741 records. After removal of 728 irrelevant studies, 13 trials were carefully examined and assessed for eligibility. Three papers were removed, one study using the ANI, the other two the SPI (Fig. 1).<sup>[12-14]</sup> Two of these studies were observational (using a historic control group) or case control studies;<sup>[13,14]</sup> the third study did not report data for the complete duration of the surgical procedure.<sup>[12]</sup> Finally, two recently published studies were added. The first is a randomized trial from our research group that compared Nociception Level (NOL)-guided analgesia with standard clinical care in patients undergoing major abdominal surgery.<sup>[15]</sup> The second study is a trial that compared SPI guided anesthesia with standard care during laparoscopic cholecystectomy.<sup>[16]</sup> Our review process therefore resulted in a total of 12 unique studies eligible for inclusion in the review.



**Figure 1.** Flow diagram of the study selection process following the PubMed search on June 30, 2018.

**Table 1.** Individual nociception monitor characteristics.

Monitor	Manufacturer	Autonomic input variables	Index	Optimal range / cut off
SPI	GE Healthcare	Pulse beat interval Pulse wave amplitude	0-100	20 – 50
ANI	MDoloris Medical systems	Heart rate variability	0-100	50
NoL	Medasense	Heart rate (variability) Pulse wave amplitude Skin conductance	0-100	10 – 25
Cardean	Alpha-2	Blood pressure Heart rate	0-100	60
Algiscan	ID med	Pupil diameter	NA	Pupil diameter increase >30%

SPI surgical plethysmographic index.

ANI analgesia nociception index;

NoL nociception level index


NA not available

### Study characteristics

Characteristics of the 12 included studies are shown in table 2 and the main findings are summarized in table 3. All publications were in English. A total of 1045 patients were studied, with 520 receiving an intervention compared to 526 treated according to routine clinical care. Care in most studies was guided using the SPI ( $n = 6$ ),<sup>[16-21]</sup> followed by the ANI ( $n = 3$ ).<sup>[22-24]</sup> The NOL, pupillometry and the beat-to-beat cardiovascular depth of anesthesia index (CARDEAN 2.0) were evaluated in single studies.<sup>[15,25,26]</sup> We will now discuss the available evidence of each separate monitor.

#### *Surgical Plethysmographic index (SPI)*

Six reports were identified that compared SPI guided anesthesia to standard practice.<sup>[16-21]</sup> All studies were diverse with regard to the maintenance hypnotic (propofol or sevoflurane) and opioids (remifentanyl/sufentanyl/fentanyl and oxycodone). The guidance of these agents was however uniform: all maintained a bispectral index or state entropy value between 40 – 60 and steered their SPI values in the intervention group to maintain values below 50. Bergman et al. and Chen et al. found that SPI monitoring reduced remifentanyl consumption during ear-, nose- and throat surgery and orthopedic surgery by 23% and 25% respectively.<sup>[17,18]</sup> Similarly, Won et al. found a 30% reduction in oxycodone consumption in SPI guided patients for thyroid surgery.<sup>[21]</sup> However, in absolute values, the reduction in oxycodone from that study equaled



to only 2.8 mg morphine. In contrast with these studies, Jain et al. found an increased consumption of fentanyl in SPI guided patients during laparoscopic cholecystectomy.<sup>[16]</sup> This translated to less postoperative pain and a reduced need for postoperative adjuvant analgesia. In general however, the effect of SPI guidance on secondary endpoints was limited. No significant differences in mean hemodynamic values were reported, although Chen et al. found that the number of episodes with inadequate anesthesia (a composite endpoint that includes hyper/hypotension and brady/tachycardia) was reduced by 80% under SPI guidance.<sup>[18]</sup> Recovery times were identical or at best 4 minutes faster with SPI guidance and apart for the study of Jain et al., no differences on postoperative pain or opioid consumption were found.<sup>[16]</sup> (see table 2). Finally, the studies of Colombo et al.<sup>[19]</sup> and Gruenewald et al.<sup>[20]</sup> found no differences on intraoperative opioid consumption or perioperative secondary outcomes at all.

*Pooled data* analysis shows that the SPI had an overall significant opioid sparing effect: mean difference in morphine equivalents  $-0.06 \text{ mg.kg}^{-1}.\text{hr}^{-1}$ , (95% CI  $-0.12$  to  $-0.00$ ,  $Z = -2.0$ ,  $p = 0.04$ ,  $I^2 = 70\%$ ), or a 8% reduction in opioid consumption. *In conclusion*, analysis of the pooled data showed that SPI guided management may reduce opioid consumption during surgery, although individual study results varied considerably. Heterogeneity was substantial due to differences in methodology, including type of surgery and choice of opioid and hypnotic agents. Therefore, no definitive conclusions can be drawn.

### *Analgesia Nociception Index (ANI)*

Three reports were identified comparing the ANI to standard of care during lumbar discectomy<sup>[24]</sup>, breast surgery<sup>[22]</sup> or laparoscopic cholecystectomy<sup>[23]</sup> (see table 2). All studies used a volatile hypnotic for maintenance (sevoflurane or desflurane). Fentanyl, remifentanyl and morphine were used for analgesia. Dundar et al. provided thoracic paravertebral blockade for all their patients receiving breast surgery.<sup>[22]</sup> This study found a significant reduction of remifentanyl consumption in the ANI guided group (30% or 33.5 mg morphine equivalents in total,  $p=0.027$ ). This significant difference in remifentanyl consumption did not translate into faster recovery times or improved pain scores in the PACU. In addition, methodological flaws (for instance, the report fails to detail data collection and blinding procedures) reduce the quality of evidence of this study. The studies of Szental et al. and Upton et al. found no

differences in opioid use during anesthesia, however opioid consumption was not the primary outcome of both studies and the use of morphine for intraoperative analgesia may not have been an ideal choice.<sup>[23,24]</sup> Regarding other endpoints, only Upton et al, found lower pain scores in ANI guided patients after lumbar discectomy or laminectomy (mean difference first 90 minutes postoperative 1.3 NRS points,  $p=0.01$ ; see table 2).<sup>[24]</sup> However total fentanyl dose in the PACU was not significantly different.

*Pooled data* analysis of these studies show that ANI guidance did not result in a significant difference in intraoperative opioid consumption: mean difference  $+0.00 \text{ mg.kg}^{-1}.\text{hr}^{-1}$  morphine (95% CI  $-0.018$  to  $0.024$ ,  $Z = 0.12$ ,  $p = 0.90$ ,  $I^2 = 98\%$ ).

*In conclusion*, current evidence coming from only 3 trials did not show a benefit of ANI guidance on intraoperative opioid consumption. Preliminary effects of ANI monitoring concerning an opioid sparing effect during breast surgery in patients that receive additional neuraxial blockade *or* on postoperative pain scores after back surgery, need to be corroborated in future studies.

#### *Nociception Level index (NOL)*

Our systematic review did not find any study that compared NOL guided anesthesia vs. standard care on intraoperative opioid consumption. However, our group recently published a trial in which NOL guided anesthesia was compared to standard care in 80 patients during major ambulatory laparoscopic and open abdominal surgery without the use of neuraxial blockade.<sup>[15]</sup> General anaesthesia was maintained with propofol (bispectral index target 40-60) and remifentanyl (intervention group NOL target 10-25), both administered using target controlled infusion. This study found a reduction in remifentanyl consumption of 28% (absolute reduction  $0.18 \text{ mg.kg}^{-1}.\text{h}^{-1}$  morphine equivalents;  $p<0.001$ ) Additionally this study found a trend towards improved hemodynamic stability. Postoperative pain scores or opioid consumption did not differ significantly (see table 2).

*In conclusion*, data from only one study indicates that NOL guided anesthesia may reduce remifentanyl consumption. Effects on other outcomes are yet uncertain. Future studies are needed.

Table 2. Properties of the included studies in this review

First Author	Year	Noception monitor (target*)	Number of patients (intervention/control)	Surgery	Anesthesia technique	Hypnosis monitor (targets)	Patients	Primary outcome	Comments
Won <sup>21</sup>	2016	SPI (20-50)	23/22	Thyroid resection	-Sevoflurane -Oxycodone -Rocuronium	BIS (40-60)	ASA 1-2; 20-65 years.	Intraoperative oxycodone consumption	Single center study. Rescue medication (thiopental) in case of somatic movement despite SPI and BIS values within target boundaries
Bergmann <sup>17</sup>	2013	SPI (20-50 and $\Delta < 10$ )	76/75	Orthopedic surgery in a supine or beach-chair position	-Propofol -Remifentanyl -Mivacurium	SE (40-60)	ASA 1-3; 18-75 years.	Propofol (1) and remifentanyl (2) consumption. Recovery time (3).	Single center study. There was maximum remifentanyl infusion rate. No difference in postoperative pain
Chen <sup>18</sup>	2010	SPI <sup>#</sup> (20-50)	40/40	ENT surgery	-Propofol TCI -Remifentanyl TCI -Rocuronium	BIS (40-60)	ASA 1-2; 18-70 years.	Number of episodes with inadequate anaesthesia <sup>s</sup>	Single center study. No difference in postoperative pain
Colombo <sup>19</sup>	2015	SPI (< 50)	30/30	Laparoscopic cholecystectomy	-Propofol TCI -Remifentanyl TCI -Cis-atracurium	SE (40-60)	ASA 1-2; 18-50 years	Sympathetic modulation	Single center study.

Table 2. Continued

First Author	Year	Noception monitor (target*)	Number of patients (intervention/control)	Surgery	Anesthesia technique	Hypnosis monitor (targets)	Patients	Primary outcome	Comments
Gruenewald <sup>20</sup>	2014	SPI (< 50)	42/40	Gynecological or Orthopedic surgery	-Sevoflurane -Sufentanil -Rocuronium	BIS (40-60)	ASA 1-2; 18-65 years	Incidence of unwanted somatic events	Single center study.
Jain <sup>16</sup>	2019	SPi (20-50)	70/70	Laparoscopic cholecystectomy	-Sevoflurane -Fentanyl	BIS (40-60)	ASA 1-2 18-65 years	Intraoperative fentanyl consumption	Single center study.
Dundar <sup>22</sup>	2018	ANI (50-70)	22/22	Breast surgery	-Sevoflurane -Remifentanyl -Thoracic paravertebral block	BIS (40-60)	ASA 1-2; females; 18-65 years.	Total remifentanyl consumption (mentioned in discussion)	Study sites not specified. All patients received a thoracic paravertebral block.
Upton <sup>24</sup>	2017	ANI (≥ 50)	24/26	Lumbar discectomy or laminectomy	-Sevoflurane -Fentanyl and non-opioid analgesia -Rocuronium	BIS (40-60)	ASA 1-2; 18-75 years.	Postoperative NRS	Single center study.
Szentali <sup>23</sup>	2015	ANI (> 50)	59/60	Laparoscopic cholecystectomy	- sevoflurane or desflurane -Fentanyl, morphine and non-opioid analgesia -Neuromuscular blocker	BIS Depth not specified	ASA ?; 18-75 years.	VAS >50 mm in first postoperative hour	Study performed in 2 centers.
Meijer <sup>15</sup>	2018	Noception Level (10-25)	40/40	Major abdominal surgery (48%), abdominal surgery (39%), gynecology (14%)	-Propofol TCI -Remifentanyl TCI -Rocuronium	BIS (45-55)	ASA 1-3; 18 - 80 years.	Propofol (1) and remifentanyl (2) consumption. Incidence of inadequate anesthesia events (3).	Single center study.

Table 2. Continued

First Author	Year	Noiception monitor (target*)	Number of patients (intervention/control)	Surgery	Anesthesia technique	Hypnosis monitor (targets)	Patients	Primary outcome	Comments
Martinez <sup>25</sup>	2010	Beat-to-beat cardiovascular index <sup>8</sup> (< 60 and absence of conventional signs of noiception)	71/75	Gastroscopy and/or colonoscopy	-Propofol TCI -Alfentanil	BIS (40-60)	ASA 1-2; 20-75 years	Reduction in unwanted movements	Single center study. Beat-to-beat blood pressure was measured using the Finapres™ device using a finger cuff.
Sabourdin <sup>26</sup>	2017	Pupillometry (pupil diameter 5-30% of baseline)	25/30	Gynecological surgery	-Propofol TCI -Remifentanyl TCI -Atracurium	BIS (40-60)	ASA 1-2; females; 18-60 years.	Remifentanyl consumption	Single center study. In case of large hemodynamic changes remifentanyl TCI could be changed and/or vasoactive medication or fluids could be given.

\* The target indicates adequate analgesia. A monitor value outside the target range leads to additional opioid administration according to the protocol of the individual studies;

# The authors named their monitoring index the surgical stress index which is equivalent to the SPI.

& the beat-to-beat cardiovascular depth of anesthesia index (CARDEAN 2.0) is a nociceptive algorithm based on changes in blood pressure and tachycardia;

\$: inadequate anesthesia: mean blood pressure >120% of baseline or > 100 mmHg or mean blood pressure < 80% of baseline or < 60 mmHg; heart rate > 90 beats/minute or <80% of baseline or <45 beats/minute; somatic arousal; somatic response

? data not available;

ANI: analgesia noiception index; BIS: bispectral index; ENT: ear-nose-and-throat; SE: state entropy; SPI: surgical plethysmographic index.

### *Cardiovascular depth of analgesia (CARDEAN 2.0)*

The systematic search yielded one study that assessed the use of the CARDEAN 2.0 monitor vs. standard care during procedural sedation for endoscopic procedures.<sup>[27]</sup> Sedation was administered with the use of target-controlled infusion propofol, aimed at a BIS of 60. Additionally, in the CARDEAN group, alfentanil could be administered when the monitor value exceeded 60. In the standard care, alfentanil could only be administered if a mandatory propofol intervention failed to achieve stability. Due to the nature of this protocol, the CARDEAN group received more doses of alfentanil, although the normalized dose (corrected for procedure time) was not significantly different. The increased use alfentanil in the CARDEAN group resulted in significantly less unwanted movements during the procedures (50% reduction,  $p=0.001$ ), but also a tendency to increased apnea.<sup>[27]</sup>

*In conclusion* limited evidence from a single center study shows an increase in opioid administration and a reduction in unwanted movements when the CARDEAN is used for procedural sedation.

### *Pupillometry*


Pupillometry vs. standard care was assessed in one study in 55 patients during major gynaecological surgery.<sup>[26]</sup> In both groups, anaesthesia was maintained with propofol, aimed at a BIS of 40 – 60. In the pupillometry group, remifentanil was dosed according to predefined changes in pupil diameter. This study found reduced remifentanil consumption in pupillometry guided patients (mean difference 0.42 mg.kg<sup>-1</sup>.h<sup>-1</sup> morphine equivalents,  $p<0.001$ ). This translated to less morphine requirement in the first 12 hours after surgery. Pain scores did not differ significantly. In addition, persistent pain was less frequent after 3 months post-surgery in pupillometry guided patients (51% in standard group vs. 13% in pupillometry group,  $p=0.004$ ). The reduced intraoperative remifentanil administration in pupillometry group resulted in more administration of nicardipine for hypertensive episodes (see table 2).<sup>[26]</sup>

*In conclusion*, data from one study indicates that pupillometry may help to reduce opioid consumption during major gynaecological surgery, with possible secondary benefits on short term (less opioid consumption) and midterm (less persistent pain). Future studies are however needed.

### Risk of bias

Risk of bias per study is shown in Figure 2A and summarized in Figure 2B. All studies were troubled by the inability to fully blind the investigators due to the nature of the intervention, *i.e.* need to either use or not-use the monitor during the surgical procedure. Setting aside this inevitable performance risk, seven studies had no additional high risk of bias domain according to the definitions of the Cochrane Handbook for Systematic Reviews of Interventions,<sup>[15-17,20,21,23,24]</sup> two studies had 1 additional high risk of bias;<sup>[18,19]</sup> and the remaining three studies had 2 or 3 additional high risks of bias domains.<sup>[22,25,26]</sup> The most common high risk of bias, apart from the performance bias, was detection bias (5 studies)<sup>[18,19,22,25,26]</sup> and other bias (3 studies).<sup>[22,25,26]</sup>

3



**Figure 2.** Evaluation of bias in the selected eleven twelve studies. **A.** Risk of bias per study according to the domains defined in the Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 (<http://handbook-5-1.cochrane.org>). **B.** Summary of bias per domain.

**Table 3.** Outcomes reported by each study.

Author	Monitor	Treatment effect on opioid consumption during anesthesia.	Absolute difference in opioid consumption (converted to morphine equivalents)	HD variables	Efficiency variables (ie. time to extubation)	Postoperative pain and opioid consumption	Other
Wong <sup>21</sup>	SPI	A 30% reduction in oxycodone consumption was observed with SPI monitoring (p = 0.012)	2.8 mg	No significant differences	Extubation time 3.4 min shorter with SPI (p=0.03)	No significant differences	
Bergmann <sup>17</sup>	SPI	Remifentanyl use was reduced by 25% in the SPI group (p < 0.05).	0.12 mg.kg <sup>-1</sup> .h <sup>-1</sup>	No differences in mean HD variables (apart from intubation: delta MAP 9 mmHg, P<0.005)	Recovery times were reduced by 3-4 min in the SPI group (p < 0.05).	No significant differences	
Chen <sup>18</sup>	SPI	Remifentanyl consumption was reduced by 23% in the SPI group (p < 0.05).	0.3 mg.kg <sup>-1</sup> .h <sup>-1</sup>	No significant difference in mean values. Number of episodes with hypertension, hypotension or bradycardia significantly reduced (p<0.01).	No significant differences	No significant differences	
Colombo <sup>19</sup>	SPI	No significant differences	NA	There was less sympathetic modulation as measured by heart rate variability indices in the SPI group (p < 0.01)	No significant differences	No significant differences	
Gruenewald <sup>20</sup>	SPI	No significant differences	NA	No differences in mean values or number of episodes.	No significant differences	No significant differences	

Table 3. Continued

Author	Monitor	Treatment effect on opioid consumption during anesthesia.	Absolute difference in opioid consumption (converted to morphine equivalents)	HD variables	Efficiency variables (i.e. time to extubation)	Postoperative pain and opioid consumption	Other
Jain <sup>16</sup>	SPI	Mean Fentanyl consumption was increased in SPI group (p=0.017)	0.024 mg.kg <sup>-1</sup> .h <sup>-1</sup>	No significant differences	Duration of surgery was 9.8 min reduced in SPI group (p=0.03)	Fentanyl consumption was 7 ug less in SPI group (p=0.01) and VAS was 0.6 points lower in SPI group (p=0.04)	
Dundar <sup>22</sup>	ANI	A 30% reduction in remifentanyl consumption was observed with ANI monitoring (p = 0.027).	33.5 mg	No significant differences	No significant differences	No significant differences	
Upton <sup>24</sup>	ANI	No significant differences	No significant differences	No significant differences (only total surgery time reported)	No significant differences	Pain scores in the first 90 min of PACU stay were on average 1.3 units lower pain scores in the ANI group (p = 0.01).	
Szental <sup>23</sup>	ANI	No significant differences	No significant differences	No significant differences	No significant differences	No significant differences	
Meijer <sup>45</sup>	NOL	Remifentanyl was reduced by 28% in NOL group (p<0.001)	0.18 mg.kg <sup>-1</sup> .h <sup>-1</sup>	No significant differences	Reversal to extubation time was 2 min shorter in NOL group (p=0.03)	No significant differences	

Table 3. Continued

Author	Monitor	Treatment effect on opioid consumption during anesthesia.	Absolute difference in opioid consumption (converted to morphine equivalents)	HD variables	Efficiency variables (i.e. time to extubation)	Postoperative pain and opioid consumption	Other
Martinez <sup>25</sup>	CARDEAN	No significant difference in alfentanil dose (corrected for duration) Increased number of patient receiving alfentanil in CARDEAN group (83% vs. 61%) There was more alfentanil use in the CARDEAN group (P < 0.05).	NA	No significant differences	No significant differences	No significant differences	There was a 50% reduction in unwanted movements with CARDEAN monitoring at BIS values < 60 (p= 0.001).
Sabourdin <sup>26</sup>	Pupillometry	Reduced remifentanyl consumption in pupillometry group (p<0.001)	0.42 mg.kg <sup>-1</sup> .h <sup>-1</sup>	More patients required nicardipine in pupillometry group (42.3% vs. 0%; p<0.001)	No significant differences	Reduced morphine consumption 0-12h (mean difference 0.1mg.kg <sup>-1</sup> )	Significant correlation between remifentanyl consumption and postoperative morphine requirements

Intraoperative opioid consumption was converted to morphine equivalents in mg.kg<sup>-1</sup>.h<sup>-1</sup> if possible.

ANI: analgesia nociception index;

BIS: bispectral index;

ENT: ear-nose-and-throat;

SE: state entropy;

SPI: surgical plethysmographic index.

## DISCUSSION

Our systematic search on the effect of nociception monitoring vs. standard care during general anesthesia on opioid consumption yielded 12 reports. Four did not find a significant difference in opioid consumption, 7 found a reduced opioid consumption — with widely varying magnitude and one study found an increased opioid consumption (see table 3). We did not conduct a planned meta-analysis because the data were so heterogeneous. However, a meta-analysis has been published before by Gruenewald et al., despite substantial heterogeneity. They found no significant effect of nociception monitoring on intraoperative opioid consumption or other secondary outcomes, apart from a reduced rate of unwanted movement.<sup>[7]</sup>

We instead performed sub-analyses of pooled data from unique monitors when more than one trial was available which was the case for the SPI and ANI monitors. These analyses found no significant effect for the ANI monitor but an opioid sparing effect for the SPI monitor of about 8% or 0.06 mg.kg<sup>-1</sup>.hr<sup>-1</sup> morphine equivalents. It is debatable whether this reduction is clinically relevant. Data from single studies concerning the NOL and pupillometry monitors also show a more substantial reduction in intraoperative opioid consumption (0.18 and 0.42 mg.kg<sup>-1</sup>.hr<sup>-1</sup> morphine equivalents respectively).<sup>[15,26]</sup> However, these results require confirmation. On secondary outcomes, no consistent beneficial effect of nociception guided management was observed, although admittedly, some individual well conducted trials show promising effects on intraoperative hemodynamic stability<sup>[15]</sup> or postoperative pain<sup>[16,26,24]</sup> (see table 2). Again, these results need to be confirmed.

Measurement of nociception under general anesthesia is challenging. In general, noxious stimuli that are perceived by the autonomic nerve system will evoke autonomic and behavioral responses. The magnitude of these responses depends on the intensity of the stimulus and the presence of any alleviating agents; *ie.* the nociception- anti nociception balance. During anesthesia, autonomic responses are noted by their effects on hemodynamic and respiratory control. Nociception monitors invariably use one or more of these autonomic variables as input for their algorithm to produce an index of nociception (see table 3). Unfortunately, these autonomic variables are not uniquely related to

nociception; any stressing or alleviating factor may cause a change in blood pressure or heart rate. In addition, both the choice of maintenance hypnotic and opioid and the type of surgical procedure profoundly affect the nociception – anti nociception balance. All these factors may reduce the specificity of nociception monitors when they are tested in the clinical setting.

We contend that nociception monitors in daily practice should be used as an aid to improve individualized antinociceptive therapy; they should not be used to maintain nociception index values within a specific range at all costs. In addition, although some trials showed a reduced opioid consumption in nociception guided patients, the use of these monitors can also result in an increased consumption of opioids for certain procedures.<sup>[16]</sup> Both ways may improve outcomes for patients, such as reduced postoperative pain. The key utility of these monitors is not reducing opioid consumption *per se*, rather to achieve the optimal dosing for the individual patient that will result in the best outcome.

### General limitations

Current data are troubled by the large heterogeneity that was present among studies. Studies differed significantly in design, study population and surgery and anesthesia type (table 1). The most commonly performed type of surgery was abdominal surgery (6 studies, some of which were laparoscopic);<sup>[19,20,15,16,26,23]</sup> other procedures included ear-nose-and-throat surgery,<sup>[18]</sup> breast surgery,<sup>[22]</sup> thyroidectomy,<sup>[21]</sup> lumbar discectomy/laminectomy,<sup>[24]</sup> and orthopedic surgery (arthroscopy of knee, shoulder or ankle).<sup>[17]</sup> Anesthesia technique varied considerably among studies: six studies used propofol for maintenance of anesthesia,<sup>[15,17-19,25,26]</sup> five combined with remifentanyl and one combined with alfentanil. The other studies used a volatile anesthetic (sevoflurane or desflurane) combined with either remifentanyl ( $n = 1$ ), fentanyl ( $n = 3$ ), oxycodone ( $n = 1$ ) or sufentanyl ( $n = 1$ ).<sup>[16,20-24]</sup> Most studies used a neuromuscular blocker ( $n = 9$ ),<sup>[15-21, 23,24,26]</sup> and one study used a thoracic paravertebral block in both intervention and standard care groups.<sup>[22]</sup> The ample differences in type of anesthesia and in the intensity of the surgical trauma may profoundly affect the individual study results. For instance, noxious stimuli during gastroscopy under propofol/alfentanil anesthesia will differ significantly in intensity from stimuli during discectomy under sevoflurane/fentanyl anesthesia or breast

surgery under sevoflurane/fentanyl surgery with a thoracic paravertebral local anesthetic block.<sup>[22,24]</sup>

Also, the comparator arm in most trials (commonly defined as *standard clinical care*) often lacked strict guidelines for opioid administration. Therefore, any effect of nociception monitoring on opioid administration could be confounded by suboptimal clinical practice of the comparator group. Finally, all studies included in our review were relatively small with fewer than 100 subjects per treatment arm, and most had fewer than 50 per arm. Additionally, all studies had a high risk of performance bias and five studies had a high risk of detection bias (Fig. 2).

### Limitations of this review

Although our search was extensive, it was limited to the PubMed database and we may have missed some relevant studies. We therefore performed a secondary search across websites of anesthesia societies to detect studies that are presented as abstracts. One possible relevant abstract was detected. Gruenewald et al. performed a multi-center, single blinded randomized-controlled trial in 494 patients studying the influence of SPI and entropy monitoring (*i.e.* combined analgesia and hypnosis monitoring) *versus* standard monitoring on signs of unwanted anesthesia events.<sup>[28]</sup> However, in their preliminary report the authors do not mention opioid consumption, which is the endpoint of this review. No other potentially relevant reports were found. Finally, we only included studies on adult patients, and we did not report on nociception monitoring in children.

## CONCLUSIONS

Current data are inconclusive about the effect of nociception monitoring on intraoperative opioid consumption or anesthesia-related outcome. Future homogeneous (randomized and open) and predefined (to reduce heterogeneity and detection risk) trials are needed to improve current level of evidence.

## REFERENCES

1. Cantineau JP, Porte F, d'Honneur G, Duvaldestin P (1994) Neuromuscular effects of rocuronium on the diaphragm and adductor pollicis muscles in anesthetized patients. *Anesthesiology* 81 (3):585-590
2. Edry R, Recea V, Dikust Y, Sessler DI (2016) Preliminary Intraoperative Validation of the Nociception Level Index: A Noninvasive Nociception Monitor. *Anesthesiology* 125 (1):193-203. doi:10.1097/ALN.0000000000001130
3. Funcke S, Sauerlaender S, Pinnschmidt HO, Saugel B, Bremer K, Reuter DA, Nitzschke R (2017) Validation of Innovative Techniques for Monitoring Nociception during General Anesthesia: A Clinical Study Using Tetanic and Intracutaneous Electrical Stimulation. *Anesthesiology* 127 (2):272-283. doi:10.1097/ALN.0000000000001670
4. Ledowski T, Burke J, Hruby J (2016) Surgical pleth index: prediction of postoperative pain and influence of arousal. *Br J Anaesth* 117 (3):371-374. doi:10.1093/bja/aew226
5. Stockle PA, Julien M, Issa R, Decary E, Brulotte V, Drolet P, Henri M, Poirier M, Latulippe JF, Dorais M, Verdonck O, Fortier LP, Richebe P (2018) Validation of the PMD100 and its NOL Index to detect nociception at different infusion regimen of remifentanyl in patients under general anesthesia. *Minerva anesthesiologica* 84 (10):1160-1168. doi:10.23736/S0375-9393.18.12720-9
6. Martini CH, Boon M, Broens SJ, Hekkelman EF, Oudhoff LA, Buddeke AW, Dahan A (2015) Ability of the nociception level, a multiparameter composite of autonomic signals, to detect noxious stimuli during propofol-remifentanyl anesthesia. *Anesthesiology* 123 (3):524-534. doi:10.1097/ALN.0000000000000757
7. Gruenewald M, Dempfle A (2017) Analgesia/nociception monitoring for opioid guidance: meta-analysis of randomized clinical trials. *Minerva anesthesiologica* 83 (2):200-213. doi:10.23736/S0375-9393.16.11602-5
8. Knotkova H, Fine PG, Portenoy RK (2009) Opioid rotation: the science and the limitations of the equianalgesic dose table. *J Pain Symptom Manage* 38 (3):426-439. doi:10.1016/j.jpainsymman.2009.06.001
9. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods G, Cochrane Statistical Methods G (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ (Clinical research ed)* 343:d5928. doi:10.1136/bmj.d5928
10. R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2018. URL <https://www.R-project.org/> Accessed July 22, 2018. (2018).
11. Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. <https://www.jstatsoft.org/article/view/> Accessed July 22 2018
12. Defresne A, Barvais L, Clement F, Bonhomme V (2018) Standardised noxious stimulation-guided individual adjustment of remifentanyl target-controlled infusion to prevent haemodynamic responses to laryngoscopy and surgical incision: A randomised controlled trial. *Eur J Anaesthesiol* 35 (3):173-183. doi:10.1097/EJA.0000000000000742
13. Le Gall L, David A, Carles P, Leuillet S, Chastel B, Fleureau C, Dewitte A, Ouattara A (2019) Benefits of intraoperative analgesia guided by the Analgesia Nociception Index (ANI) in bariatric surgery: An unmatched case-control study. *Anaesth Crit Care Pain Med* 38 (1):35-39. doi:10.1016/j.accpm.2017.09.004
14. Rogobete AF, Sandesc D, Cradigati CA, Sarandan M, Papurica M, Popovici SE, Vernic C, Bedreag OH (2018) Implications of Entropy and Surgical Pleth Index-guided general anaesthesia on clinical outcomes in critically ill polytrauma patients. A prospective observational non-randomized single centre study. *Journal of clinical monitoring and computing* 32 (4):771-778. doi:10.1007/s10877-017-0059-2

15. Meijer F, Martini C, Broens S, Boon M, Niesters M, Aarts L, Olofsen E, van Velzen M, Dahan A (2019) Nociception-guided versus Standard Care during Remifentanil-Propofol Anesthesia: A Randomized Controlled Trial. February 26, 2019. doi:10.1097/ALN.0000000000002634 (*epub ahead of print*)
16. Jain N, Gera A, Sharma B, Sood J, Chugh P (2019) Comparison of surgical pleth index guided analgesia using fentanyl versus conventional analgesia technique in laparoscopic cholecystectomy. *Minerva anesthesiologica*. doi:10.23736/S0375-9393.18.12954-3
17. Bergmann I, Gohner A, Crozier TA, Hesjedal B, Wiese CH, Popov AF, Bauer M, Hinz JM (2013) Surgical pleth index-guided remifentanil administration reduces remifentanil and propofol consumption and shortens recovery times in outpatient anaesthesia. *Br J Anaesth* 110 (4):622-628. doi:10.1093/bja/aes426
18. Chen X, Thee C, Gruenewald M, Wnent J, Illies C, Hoecker J, Hanss R, Steinfath M, Bein B (2010) Comparison of surgical stress index-guided analgesia with standard clinical practice during routine general anaesthesia: a pilot study. *Anesthesiology* 112 (5):1175-1183. doi:10.1097/ALN.0b013e3181d3d641
19. Colombo R, Raimondi F, Rech R, Castelli A, Fossali T, Marchi A, Borghi B, Corona A, Guzzetti S (2015) Surgical Pleth Index guided analgesia blunts the intraoperative sympathetic response to laparoscopic cholecystectomy. *Minerva Anesthesiologica* 81 (8):837-845
20. Gruenewald M, Willms S, Broch O, Kott M, Steinfath M, Bein B (2014) Sufentanil administration guided by surgical pleth index vs standard practice during sevoflurane anaesthesia: a randomized controlled pilot study. *Br J Anaesth* 112 (5):898-905. doi:10.1093/bja/aet485
21. Won YJ, Lim BG, Lee SH, Park S, Kim H, Lee IO, Kong MH (2016) Comparison of relative oxycodone consumption in surgical pleth index-guided analgesia versus conventional analgesia during sevoflurane anaesthesia: A randomized controlled trial. *Medicine (Baltimore)* 95 (35):e4743. doi:10.1097/MD.00000000000004743
22. Dunder N, Kus A, Gurkan Y, Toker K, Solak M (2018) Analgesia nociception index (ani) monitoring in patients with thoracic paravertebral block: a randomized controlled study. *Journal of clinical monitoring and computing* 32 (3):481-486. doi:10.1007/s10877-017-0036-9
23. Szental JA, Webb A, Weeraratne C, Campbell A, Sivakumar H, Leong S (2015) Postoperative pain after laparoscopic cholecystectomy is not reduced by intraoperative analgesia guided by analgesia nociception index (ANI(R)) monitoring: a randomized clinical trial. *Br J Anaesth* 114 (4):640-645. doi:10.1093/bja/aeu411
24. Upton HD, Ludbrook GL, Wing A, Sleight JW (2017) Intraoperative "Analgesia Nociception Index"-Guided Fentanyl Administration During Sevoflurane Anesthesia in Lumbar Discectomy and Laminectomy: A Randomized Clinical Trial. *Anesth Analg* 125 (1):81-90. doi:10.1213/ANE.0000000000001984
25. Martinez JY, Wey PF, Lions C, Cividjian A, Rabilloud M, Bissery A, Bourdon L, Puidupin M, Escarmet J, Quintin L (2010) A beat-by-beat cardiovascular index, CARDEAN: a prospective randomized assessment of its utility for the reduction of movement of movement during colonoscopy. *Anesth Analg* 110 (3):765-772. doi:10.1213/ANE.0b013e3181cc9ebe
26. Sabourdin N, Barrois J, Louvet N, Rigouzzo A, Guye ML, Dadure C, Constant I (2017) Pupillometry-guided Intraoperative Remifentanil Administration versus Standard Practice Influences Opioid Use: A Randomized Study. *Anesthesiology* 127 (2):284-292. doi:10.1097/ALN.0000000000001705
27. Rossi M, Cividjian A, Fevre MC, Oddoux ME, Carcey J, Halle C, Frost M, Gardellin M, Payen JF, Quintin L (2012) A beat-by-beat, on-line, cardiovascular index, CARDEAN, to assess circulatory responses to surgery: a randomized clinical trial during spine surgery. *J Clin Monit Comput* 26 (6):441-449. doi:10.1007/s10877-012-9372-y
28. Grünewald M, Harjuz J, Preckel B, Moinár Z, Yli-Hankalas A, Beins B (2018) Comparison of Adequacy of Anaesthesia monitoring with Standard clinical practice during routine general anaesthesia: an international, multi-centre, single-blinded randomized controlled trial. Abstract 1718. Paper presented at the Euroanaesthesia, Copenhagen, June 3

